Teva Pharmaceutical Industries Limited TEVA announced positive top line results from a phase III study HALO evaluating its pipeline candidate fremanezumab TEV 48125 for prevention of chronic migraine CM The study met both its primary and secondary end points The company will
June 02, 2017 at 06:52AM
from
No comments:
Post a Comment